Cwm, LLC Immunocore Holdings PLC Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Cwm, LLC holds 1,111 shares of IMCR stock, worth $35,152. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,111

Previous 1,527 27.24%

Holding current value

$35,152

Previous $52,000 32.69%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	SELL	$30.06 - $41.49 $12,504 - $17,259	-416 Reduced 27.24%	1,111 $35,000
Q2 2024 Jul 09, 2024	SELL	$33.78 - $63.75 $571,523 - $1.08 Million	-16,919 Reduced 91.72%	1,527 $52,000
Q1 2024 Apr 05, 2024	SELL	$60.14 - $75.36 $347,549 - $435,505	-5,779 Reduced 23.86%	18,446 $1.2 Million
Q4 2023 Feb 01, 2024	SELL	$42.85 - $69.5 $1.25 Million - $2.03 Million	-29,176 Reduced 54.64%	24,225 $1.66 Million
Q3 2023 Oct 11, 2023	SELL	$49.5 - $66.6 $105,534 - $141,991	-2,132 Reduced 3.84%	53,401 $2.77 Million
Q2 2023 Aug 03, 2023	SELL	$48.54 - $61.64 $105,574 - $134,067	-2,175 Reduced 3.77%	55,533 $3.33 Million
Q1 2023 Apr 28, 2023	SELL	$46.12 - $65.71 $126,230 - $179,848	-2,737 Reduced 4.53%	57,708 $2.85 Million
Q4 2022 Feb 01, 2023	SELL	$45.51 - $65.08 $463,701 - $663,100	-10,189 Reduced 14.43%	60,445 $3.45 Million
Q3 2022 Oct 27, 2022	SELL	$37.34 - $57.44 $89,690 - $137,970	-2,402 Reduced 3.29%	70,634 $3.32 Million
Q2 2022 Jul 28, 2022	BUY	$25.46 - $37.72 $1.86 Million - $2.75 Million	73,036 New	73,036 $2.73 Million

Others Institutions Holding IMCR

# of Institutions

135

Shares Held

40.8M

Call Options Held

197K

Put Options Held

451K

View Full List

About Immunocore Holdings plc

Ticker IMCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,897,100
Market Cap $1.39B
Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...

More about IMCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account